Daily Market Research Report

March 18, 2026

Alpha Signal Monitor

Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.

Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts

Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM

This report is generated using advanced AI research capabilities with real-time market data access.

Gold ETFs: Institutional Outlook (as of March 18, 2026)

Trading Idea: Buy Rationale (TL;DR): Street consensus across leading banks skews bullish into 2H26–YE26, with price targets clustered around $4,800–$6,300/oz and the strongest calls anchored in persistent central‑bank demand, resumed ETF inflows, and an expected Fed easing path. UBS CIO guides to $6,200 for most of 2026 and JPMorgan sees $6,300 by year‑end, reinforcing a constructive backdrop for GLD/IAU/BAR as spot trackers. (ubs.com)

Macro uncertainty (policy credibility, geopolitics, elevated fiscal deficits) plus falling real rates underpin gold’s role as a portfolio hedge in 2026; UBS CIO remains long with $6,200/oz targets for Mar–Sep 2026 (moderating to $5,900 by Dec), while JPMorgan’s end‑2026 target is $6,300. (ubs.com)

Key Drivers - Ongoing central‑bank reserve diversification and strong official‑sector purchases. - Resumed and growing investment demand (ETFs, bars/coins) as rates decline and policy/geopolitical risks stay elevated. - Potential USD softness alongside easier Fed policy supporting non‑yielding assets. - “Debasement”/fiscal concerns drawing private capital into real assets, per recent bank commentary. - Tight mine supply response relative to demand growth.

Risk Considerations - Hawkish Fed pivot or upside surprises in real yields/USD that sap investment demand. - Sharp slowdown in or reversal of central‑bank purchases; renewed ETF outflows. - Faster‑than‑expected global growth, easing geopolitics, or policy stabilization reducing safe‑haven bids. - Volatility spikes and crowded positioning prompting drawdowns; pro‑cyclical deleveraging in risk‑off episodes. - Regulatory/tax changes affecting bullion‑backed ETFs or physical markets.

Position GLD/IAU/BAR as core hedges within a diversified sleeve; prefer adding on pullbacks and scaling exposure given elevated volatility. Use lower‑fee wrappers (IAU, BAR) for strategic holdings and GLD for liquidity‑sensitive mandates; reassess sizing if real yields/USD inflect higher or official‑sector demand wobbles.

Stock Ratings

Error retrieving stock ratings information: Request timed out.

IPO Calendar

Timeframe: March 18, 2026 to April 18, 2026 (U.S. equity markets)

The U.S. IPO/calendar over the next month is light but active around select sectors: a large real‑estate carve‑out (Janus Living), a small‑cap cross‑border resources ADS listing (Guardian Metal Resources), one direct listing (The Metals Royalty Company), and at least one clinical‑stage biotech (Salspera) aiming to price during the week of March 23, 2026. Dates are often set only 7–10 days in advance, so beyond late March visibility is limited. (axios.com)

Janus Living, Inc. (JAN)

• Expected listing date: 2026-03-20 (estimated)
• Price range: $18.00 – $20.00
• Shares offered: 37,000,000 (base)
• Exchange: NYSE
• Lead underwriters: BofA Securities, J.P. Morgan
• Business summary: Pure‑play senior housing REIT formed by Healthpeak Properties to own and operate 34 senior‑housing communities (10,422 units) using RIDEA structures; Healthpeak intends to remain majority owner and external manager post‑IPO.
• Notes: Timing and terms are subject to change; estimated listing date based on third‑party IPO calendar. Healthpeak disclosed the public S‑11 filing on Feb 27, 2026; underwriter lineup shown on Renaissance Capital’s calendar. (s202.q4cdn.com)
• Sources: Healthpeak press release: public S‑11 filing for Janus Living (Feb 27, 2026). (s202.q4cdn.com), Healthpeak investor presentation (Feb 27, 2026): Janus Living summary. (s202.q4cdn.com), StockAnalysis IPO page (date/terms snapshot). (stockanalysis.com), Renaissance Capital IPO calendar (underwriters shown). (renaissancecapital.com)

Guardian Metal Resources PLC (GMTL)

• Expected listing date: 2026-03-20 (estimated)
• Shares offered: 3,058,100 ADS (base; subject to change)
• Exchange: NYSE American
• Lead underwriters: BMO Capital Markets
• Business summary: U.S.‑focused exploration‑stage critical‑minerals company (notably tungsten) with projects in Nevada; pursuing a U.S. ADS offering and dual‑listing alongside existing London AIM ordinary shares.
• Notes: Filed an F‑1 on Feb 26, 2026. Deal size and share count have been signaled by IPO trackers but may change; the preliminary F‑1 does not show a final price range. (sec.gov)
• Sources: SEC Form F‑1 (Feb 26, 2026): Guardian Metal Resources PLC; BMO listed in ‘Underwriters’. (sec.gov), Renaissance Capital note: tungsten miner files for $50m U.S. IPO. (stockanalysis.com), StockAnalysis IPO page (estimated date/size). (stockanalysis.com)

The Metals Royalty Company Inc. (TMCR)

• Expected listing date: 2026-03-23 (estimated)
• Exchange: Nasdaq Capital Market
• Business summary: Critical‑metals and minerals royalty/streaming company; listing in the U.S. via a direct listing (no primary capital raise).
• Notes: Direct listing (not a traditional underwritten IPO); Stifel designated financial advisor under Nasdaq Rule 4120(c)(8). Expected to begin trading on or about March 2026, per F‑1. (sec.gov)
• Sources: SEC Form F‑1 (Feb 27, 2026): direct listing mechanics; Stifel named financial advisor; Nasdaq Capital Market listing under ‘TMCR’. (sec.gov), StockAnalysis IPO page (estimated date). (stockanalysis.com)

Salspera, Inc. (TKVA)

• Price range: $14.00 – $16.00
• Shares offered: 5,666,666 (base); up to 850,000 additional (over‑allotment)
• Exchange: Nasdaq
• Lead underwriters: Kingswood Capital Partners, LLC (sole bookrunner)
• Business summary: Clinical‑stage biotech developing live bacterial immunotherapies for solid tumors; lead candidate Saltikva (attenuated Salmonella engineered to express IL‑2) targeting metastatic pancreatic cancer (Phase 3 funding need).
• Notes: Issuer Free Writing Prospectus indicates expected pricing in the week of March 23, 2026; final date subject to SEC effectiveness and market conditions. (sec.gov)
• Sources: SEC Issuer Free Writing Prospectus (Mar 3–4, 2026): ticker, share count, price range, bookrunner, expected timing. (sec.gov), SEC preliminary S‑1 (Feb 2, 2026): company background/risk factors. (sec.gov), Renaissance ‘Week Ahead’ note (late Feb 2026): Salspera terms/timing. (renaissancecapital.com), FierceBiotech coverage (Mar 11, 2026). (fiercebiotech.com)

IPO dates and terms change frequently, and many offerings set dates only a week in advance; items labeled ‘estimated’ may slip or accelerate. Direct listings (e.g., TMCR) are not underwritten IPOs and may not raise primary capital. Always confirm pricing and effective-date updates from the SEC filings, issuer press releases, and exchange calendars before trading. (stockanalysis.com)

Sources

• IPO Calendar: https://s202.q4cdn.com/584270836/files/doc_news/Healthpeak-Properties-Inc--Announces-Public-Filing-of-Registration-Statement-with-the-SEC-for-Janus-Living-Inc--2026.pdf?utm_source=openai, https://s202.q4cdn.com/584270836/files/doc_presentations/2026/Feb/27/Healthpeak-February-27-2026-Investor-Presentation_vF.pdf?utm_source=openai, https://stockanalysis.com/ipos/calendar/, https://stockanalysis.com/stocks/gmtl/, https://stockanalysis.com/stocks/jan/, https://stockanalysis.com/stocks/tmcr/, https://www.axios.com/newsletters/axios-pro-rata-64cecfe2-b486-4665-8e5d-a2cabece30b5?utm_source=openai, https://www.fiercebiotech.com/biotech/salspera-plans-91m-ipo-fund-phase-3-studies-salmonella-based-cancer-therapy?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/Calendar, https://www.renaissancecapital.com/IPO-Center/News/117345/US-IPO-Week-Ahead-Medtronic-carve-out-MiniMed-to-kick-off-March-calendar?utm_source=openai, https://www.sec.gov/Archives/edgar/data/2039972/000110465926020524/tm2532978-6_f1.htm, https://www.sec.gov/Archives/edgar/data/2084032/000121390026010732/ea0256863-04.htm?utm_source=openai, https://www.sec.gov/Archives/edgar/data/2084032/000121390026023531/ea0279573-fwp_salspera.htm?utm_source=openai, https://www.sec.gov/Archives/edgar/data/2087398/000110465926021062/tm2526563-10_f1.htm

Disclaimer

This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.

Generated on: 2026-03-18 at 11:51 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.

Powered by Alpha Signal Monitor | Market Intelligence Through AI